It was reported that breast cancer rarely possessed ERK pathway kinases mutations, BRAF (2%), KRAS (5%), and HRAS (1%) mutations occur at even lower frequency in TNBC [15, 16], only a few of studies recognized breast cancer as a good candidate of ERK pathway targeting therapy. The gene discussed is KRAS; the disease is breast carcinoma.